Russell Investments Group Ltd. Reduces Stock Position in Omnicell, Inc. $OMCL

Russell Investments Group Ltd. reduced its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 17.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 86,462 shares of the company’s stock after selling 18,635 shares during the period. Russell Investments Group Ltd. owned approximately 0.18% of Omnicell worth $3,023,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in OMCL. Johnson Financial Group Inc. purchased a new position in shares of Omnicell in the 4th quarter worth $37,000. Point72 Hong Kong Ltd purchased a new position in shares of Omnicell during the 4th quarter worth about $101,000. Corton Capital Inc. purchased a new position in shares of Omnicell during the 4th quarter worth about $208,000. Caption Management LLC purchased a new position in shares of Omnicell during the 4th quarter worth about $223,000. Finally, New Age Alpha Advisors LLC purchased a new position in shares of Omnicell during the 1st quarter worth about $233,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Trading Up 5.4%

Shares of OMCL opened at $33.62 on Monday. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74. The company has a 50-day moving average of $29.62 and a 200 day moving average of $31.78. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of 67.24, a PEG ratio of 9.81 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same quarter last year, the business posted $0.51 EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on OMCL. Piper Sandler dropped their price target on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 11th. Wall Street Zen cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company lifted their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, July 21st. Finally, Bank of America lifted their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 23rd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.